

IOtest® CD7-PC5

REF IM3613
100 tests; 1 mL
10 µL / test



IOtest
Conjugated Antibody



ENGLISH	Specifications
Specificity	CD7
Clone	8H8.1
Hybridoma	P3 X 63.Ag8 X Balb/c
Immunogen	Human thymocytes
Immunoglobulin	IgG2a
Species	Mouse
Source	Ascites
Purification	Protein A affinity chromatography
Fluorochrome	Phycoerythrin cyanin 5.1 (PC5)
λ excitation	488 nm
Emission peak	670 nm
Buffer	PBS pH 7.2 plus 2 mg / mL BSA and 0.1% NaN ₃

USE

This fluorochrome-conjugated antibody permits the identification and numeration of cell populations expressing the CD7 antigen present in human biological samples using flow cytometry.

PRINCIPLE

This test is based on the ability of specific monoclonal antibodies to bind to the antigenic determinants expressed by leucocytes.

Specific staining of the leucocytes is performed by incubating the sample with the IOtest reagent. The red cells are then removed by lysis and the leucocytes, which are unaffected by this process, are analyzed by flow cytometry.

The flow cytometer measures light diffusion and the fluorescence of cells. It makes possible the delimitation of the population of interest within the electronic window defined on a histogram, which correlates the orthogonal diffusion of light (Side Scatter or SS) and the diffusion of narrow-angle light (Forward Scatter or FS). Other histograms combining two of the different parameters available on the cytometer, can be used as supports in the gating stage depending on the application chosen by the user.

The fluorescence of the so delimited cells is analyzed in order to distinguish the positively-stained events from the unstained ones. The results are expressed as a percentage of positive events in relation to all the events acquired by the gating.

EXAMPLES OF CLINICAL APPLICATIONS

Analysis of the expression of the CD7 antigen as a T cell line marker, in combination with those of the CD3 and CD5 antigens, is useful in the diagnosis of T cell proliferative syndromes such as acute lymphoblastic leukaemias (T-ALL) and prolymphocyte T cell leukaemias (1 – 4). Their use, in parallel with other myeloid markers (myeloperoxidase and CD33) and from the B cell line (CD79 and CD19), permits the identification of over 98 % of acute leukaemias (1).

The absence of expression of CD7, or its abnormal expression, can provide useful information in the case of a Sezary's syndrome or chronic lymphoid leukaemia (CLL) (1). The CD7 antigen can be expressed by certain acute immature myeloid leukaemias (AMLs) (1).

The use of scoring methods has been proposed for the classification of acute biphenotypic leukaemias (5). In this context, the CD7 antigen is considered more as being an indicator of the undifferentiated nature of a neoplasm rather than as a marker for the T cell line (5).

STORAGE AND STABILITY

The conjugated liquid forms must be kept at between 2 and 8°C and protected from light, before and after the vial has been opened.

Stability of closed vial: see expiry date on vial.
Stability of open vial: the reagent is stable for 90 days.

PRECAUTIONS

1. Do not use the reagent beyond the expiry date.
2. Do not freeze.
3. Let it come to room temperature (18 – 25°C) before use.
4. Minimize exposure to light.
5. Avoid microbial contamination of the reagents, or false results may occur.
6. Antibody solutions containing sodium azide (NaN₃) should be handled with care. Do not ingest and avoid contact with the skin, mucosa and eyes.
Moreover, in an acid medium, sodium azide can form the potentially dangerous hydrazoic acid. If it needs to be disposed of, it is recommended that the reagent be diluted in a large volume of water before pouring it into the drainage system so as to avoid the accumulation of sodium azide in metal pipes and to prevent the risk of explosion.
7. All blood samples must be considered as potentially infectious and must be handled with care (in particular: the wearing of protective gloves, gowns and goggles).
8. Never pipette by mouth and avoid all contact of the samples with the skin, mucosa and eyes.
9. Blood tubes and disposable material used for handling should be disposed of in ad hoc containers intended for incineration.

SAMPLES

Venous blood or bone marrow samples must be taken using sterile tubes containing an EDTA salt as the anticoagulant. The use of other anticoagulants is not recommended.

The samples should be kept at room temperature (18 – 25°C) and not shaken. The sample should be homogenized by gentle agitation prior to taking the test sample.

The samples must be analyzed within 24 hours of venipuncture.

METHODOLOGY

NECESSARY MATERIAL NOT SUPPLIED

- Sampling tubes and material necessary for sampling.
- Automatic pipettes with disposable tips for 10, 100 and 500 µL.
- Plastic haemolysis tubes.
- Calibration beads. For example: Flow-Set™ Fluorospheres (Ref. 6607007).
- Red cell lysis reagent with washing stage after lysis. For example: VersaLyse™ (Ref. A09777).
- Leucocyte fixation reagent. For example: IOtest 3 Fixative Solution (Ref. A07800).
- Isotypic control: IOtest reagent Mouse IgG2a-PC5 (Ref. A09149).

- Buffer (PBS: 0.01 M sodium phosphate; 0.145 M sodium chloride; pH 7.2).
- Centrifuge.
- Automatic agitator (Vortex type).
- Flow cytometer.

PROCEDURE

NOTE: The procedure below is valid for standard applications. Sample and/or VersaLyse volumes for certain Beckman Coulter applications may be different. If such is the case, follow the instructions on the application's technical leaflet. For each sample analyzed, in addition to the test tube, one control tube is required in which the cells are mixed in the presence of the isotypic control (Ref. A09149).

1. Add 10 µL of specific IOtest conjugated antibody to each test tube, and 10 µL of the isotypic control to each control tube.
2. Add 100 µL of the test sample to both tubes. Vortex the tubes gently.
3. Incubate for 15 to 20 minutes at room temperature (18 – 25°C), protected from light.
4. Then perform lysis of the red cells, if necessary, by following the recommendations of the lysis reagent used. As an example, if you wish to use VersaLyse (Ref. A09777), refer to the leaflet and follow preferably the procedure called "with concomitant fixation", which consists of adding 1 mL of the "Fix-and-Lyse" mixture prepared extemporaneously. Vortex immediately for one second and incubate for 10 minutes at room temperature, protected from light.
If the sample does not contain red cells, add 2 mL of PBS.
5. Centrifuge for 5 minutes at 150 x g at room temperature.
6. Remove the supernatant by aspiration.
7. Resuspend the cell pellet using 3 mL of PBS.
8. Repeat step 5.
9. Remove the supernatant by aspiration and resuspend the cell pellet using:
 - 0.5 mL or 1 mL of PBS plus 0.1% of formaldehyde if the preparations are to be kept for more than 2 hours and less than 24 hours. (A 0.1% formaldehyde PBS can be obtained by diluting 12.5 µL of the IOtest 3 Fixative Solution (Ref. A07800) at its 10X concentration in 1 mL of PBS).
 - 0.5 mL or 1 mL of PBS without formaldehyde, if the preparations are to be analyzed within 2 hours.

NOTE: In all cases, keep the preparations between 2 and 8°C and protected from light.

PERFORMANCE

SPECIFICITY

The CD7 antigen is a monomeric transmembranous glycoprotein with a molecular weight of 40 KDa. The distal extracellular part of the protein is composed of a unique section of the "immunoglobulin variable region" type. The CD7 molecule is expressed early during T cell ontogeny (extra-thymic prothymocyte stage) and persists up to the mature T cell lymphocyte stage (6 – 8). The CD7 antigen is present on thymocytes, on the majority of circulating T cell lymphocytes, on NK cells, on a sub-population of pre-B lymphocytes, on B cell lymphocytes originating from foetal bone marrow and on haematopoietic pluripotent stem cells (9, 10). On the other hand, mature B cell lymphocytes, and cells of erythrocytic, myeloid and megakaryocytic origin do not express CD7 (6, 10).

The monoclonal antibody 8H8.1 was assigned to CD7 during the 2nd HLDA workshop on Human Leucocyte Differentiation Antigens, Workshop held in Boston, United States, in 1984 (WS Code: 38, Section T) (11).

LINEARITY

To test the linearity of staining of this reagent, a positive cell line (CEM) and a negative cell line (DAUDI) were mixed in different proportions with a constant final number of cells, so that the positive / negative cell line ratio of the mixture ranged from 0 to 100%.

Aliquots were stained using the procedure described above and linear regression between the expected values and the observed values was calculated.

Specificity	Linear regression	Linearity (R ²)
CD7	Y = 0.9946 X - 0.2241	0.9995

EXPECTED VALUES

Each laboratory must compile a list of reference values based upon a group of healthy donors from the local population. This must be done by taking age, sex and ethnic group into account,

as well as any other potential regional differences.

In our laboratories, the whole blood samples of 50 healthy adults were used. The results obtained for the count of the positive events of interest are given in the table below:

Lymphocytes	Number	Mean (%)	SD	CV (%)
CD7 ⁺	50	77.56	6.40	8

INTRA-LABORATORY REPRODUCIBILITY

On the same day and using the same cytometer, 12 measurements of the positivity of a sample containing positive cells (peripheral blood from the same donor) were carried out. The results obtained are summarized in the following table:

Lymphocytes	Number	Mean (%)	SD	CV (%)
CD7 ⁺	12	87.73	0.38	0.43

INTER-LABORATORY REPRODUCIBILITY

On the same day and on the same sample containing positive cells (peripheral blood from the same donor), 12 measurements of the positivity were carried out by two technicians and the preparations analyzed using two different cytometers. The results obtained are summarized in the following table:

Cytometer n° 1:

Lymphocytes	Number	Mean (%)	SD	CV (%)
CD7 ⁺	12	87.73	0.38	0.43

Cytometer n° 2:

Lymphocytes	Number	Mean (%)	SD	CV (%)
CD7 ⁺	12	88.28	0.21	0.23

LIMITATIONS OF THE TECHNIQUE

1. Flow cytometry may produce false results if the cytometer has not been aligned perfectly, if fluorescence spillover have not been correctly compensated for and if the regions have not been carefully positioned.

2. It is preferable to use a RBC lysis technique with a washing step as this reagent has not been optimized for "no wash" lysis techniques.
3. Accurate and reproducible results will be obtained as long as the procedures used are in accordance with the technical insert leaflet and compatible with good laboratory practices.
4. The conjugated antibody of this reagent is calibrated so as to offer the best specific signal/non-specific signal ratio. Therefore, it is important to adhere to the reagent volume/sample volume ratio in every test.
5. In the case of a hyperleucocytosis, dilute the specimen in PBS so as to obtain a value of approximately 5×10^9 leucocytes/L.
6. In certain disease states, such as severe renal failure or haemoglobinopathies, lysis of red cells may be slow, incomplete or even impossible. In this case, it is recommended to isolate mononucleated cells using a density gradient (Ficoll, for example) prior to staining.

MISCELLANEOUS

See the Appendix for examples and references.

TRADEMARKS

The BECKMAN COULTER logo, Beckman Coulter, Flow-Set, IOTest and VersaLyse are registered trademarks of Beckman Coulter, Inc.

MANUFACTURED BY:

IMMUNOTECH
a Beckman Coulter Company
130 avenue de Lattre de Tassigny
B.P. 177 – 13276 Marseille Cedex 9
France
Customer Services: (33) 4 91 17 27 27

www.beckmancoulter.com




APPENDIX TO REF IM3613

EXAMPLES

The graph below is a biparametric representation (Side Scatter versus Fluorescence Intensity) of lysed normal whole blood sample. Staining is with IO₁Test CD7-PC5 Conjugated Antibody (Ref. IM3613). All leucocytes are represented.

Analysis is performed with a CYTOMICS FC 500 flow cytometer equipped with CXP Analysis Software.



REFERENCES

1. Rothe, G., Schmitz, G., Adorf, D., Barlage, S., Gramatzki, M., Höffkes, H.G., Janossy, G., Knüchel, R., Ludwig, W.D., Nebe, T., Nerl, C., Orfao, A., Serke, S., Sonnen, R., Tichelli, A., Wörmann, B., "Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies", 1996, *Leukemia*, 10, 877-895.
2. Jennings, C.D., Foon, K.A., "Recent advances in flow cytometry: Application to the diagnosis of hematologic malignancy", 1997, *Blood*, 8, 90, 2863-2892.
3. Rosenberg, S.A., "Classification of lymphoid neoplasms", 1994, *Blood*, 5, 84, 1359-1360.
4. Stewart, C.C., Behm, F.G., Carey, J.L., Cornbleet, J., Duque, R.E., Hudnall, S.D., Hurtubise, P.E., Loken, M., Tubbs, R.R., Wormsley, S., "U.S. Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Selection of antibody combinations", 1997, *Cytometry*, 30, 231-235.
5. Bene, M.C., Castoldi, G., Knapp, W., Ludwig, W.D., Matutes, E., Orfao, A., van't Veer, M.B., "Proposals for the immunological classification of acute leukemias", 1995, *Leukemia*, 9, 1783-1786.
6. Chang, K.L., Weiss, L.M., "CD7 : a review", 1994, *Appl. Immunohistochem.*, 3, 2, 146-156.
7. Civin, C.I., Gore, S.D., "Antigenic analysis of hematopoiesis : a review", 1993, *J. Hematol.*, 2, 137-144.
8. Mossalayi, D., Dalloul, A.H., Bertho, J.M., Lecron, J.C., De Laforest, P.G., Debre, P., "In vitro differentiation and proliferation of purified human thymic and bone marrow CD7+CD2- T-cell precursors", 1990, *Exp. Hematol.*, 18, 326-331.
9. Grümayer, E.R., Griesinger, F., Hummel, D.S., Brunning, R.D., Kersey, J.H., "Identification of novel B-lineage cells in human fetal bone marrow that coexpress CD7", 1991, *Blood*, 1, 77, 64-68.
10. Lazarovits, A.I., Colvin, R.B., Camerini, D., Karsh, J., Kurnick, J.T., "Modulation of CD7 is associated with T-lymphocyte function", 1987, *Leucocyte Typing III, White Cell Differentiation Antigens*, A.J. McMichael, 219-223.
11. Palker, T.J., Searce, R.M., Hensley, L.L., Ho, W., Haynes, B.F., "Comparison of the CD7 (3A1) group of T cell workshop antibodies", 1985, *Leucocyte Typing II, Human T lymphocytes*, Reinherz, E.L., et al. Eds., 303-313.